In vitro and in vivo Activity of Combinations of Polymyxin B with Other Antimicrobials Against Carbapenem-Resistant .

Hui Zhang, Yunzhu Zhu, Ning Yang, Qinxiang Kong, Yahong Zheng, Na Lv, Haoran Chen, Chengcheng Yue, Yanyan Liu, Jiabin Li, Ying Ye
Author Information
  1. Hui Zhang: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  2. Yunzhu Zhu: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  3. Ning Yang: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China. ORCID
  4. Qinxiang Kong: Department of Infectious Diseases, The Chaohu Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  5. Yahong Zheng: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  6. Na Lv: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  7. Haoran Chen: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  8. Chengcheng Yue: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  9. Yanyan Liu: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  10. Jiabin Li: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.
  11. Ying Ye: Department of Infectious Disease, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, People's Republic of China.

Abstract

PURPOSE: To study the in vitro and in vivo antibacterial activities of polymyxin B (PB) and other five antimicrobial agents, including imipenem (IMP), meropenem (MEM), tigecycline (TGC), sulbactam (SUL), and rifampicin (RIF), alone or in combination against carbapenem-resistant (CRAB).
METHODS: Microbroth dilution method was used to determine the minimum inhibitory concentration (MIC) of ten strains of CRAB against six antibacterial drugs, and the checkerboard method was used to determine the fractional inhibitory concentration index (FICI). A mouse pneumonia model was established by intranasal instillation of Ab5075 to evaluate the antibacterial activity in vivo.
RESULTS: The resistance rate of ten CRAB strains to IMP, MEM, and SUL was 100%, that to PB and TGC was 0%, and that to RIF was 20%. When PB was used in combination with the other five antibiotics in vitro, it mainly showed synergistic and additive effects on CRAB. The synergistic effect of PB and RIF was maximal, followed by MEM and IMP but was weak with SUL and TGC. In vivo, compared to the model group (untreated with antibiotics), treatment group (six antibiotics alone and PB combined with the other five antibiotics) reduced the bacterial load in the lung tissue and the serum inflammatory factors (IL-1β, IL-6, and TNF-α). The bacterial load and the inflammatory factors of the combined group decreased significantly than that of the single group (<0.05). The IL-6 and TNF-α values of the PB combined with the RIF group were significantly lower than the two drugs used individually.
CONCLUSION: The combination of PB and IMP, MEM, and RIF exerted robust in vitro synergistic effects on CRAB isolates. The combination of PB and the other five antimicrobial agents had a better effect in the mouse pneumonia model than single agent, while the combination of PB and RIF had the best effect.

Keywords

References

  1. Int J Infect Dis. 2013 Jun;17(6):e454-60 [PMID: 23522637]
  2. Int J Antimicrob Agents. 2008 May;31(5):434-9 [PMID: 18328674]
  3. Clin Microbiol Rev. 2008 Jul;21(3):538-82 [PMID: 18625687]
  4. Ther Adv Infect Dis. 2016 Feb;3(1):15-21 [PMID: 26862399]
  5. Int J Antimicrob Agents. 2005 Jun;25(6):523-9 [PMID: 15885987]
  6. Lancet Infect Dis. 2018 Apr;18(4):391-400 [PMID: 29456043]
  7. Essays Biochem. 2017 Mar 3;61(1):115-125 [PMID: 28258235]
  8. J Clin Microbiol. 2007 Jan;45(1):227-30 [PMID: 17093026]
  9. J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i11-6 [PMID: 18684702]
  10. Int J Antimicrob Agents. 2013 Feb;41(2):110-6 [PMID: 23127485]
  11. J Antimicrob Chemother. 2010 Jun;65(6):1119-25 [PMID: 20378670]
  12. Lancet Infect Dis. 2018 Mar;18(3):318-327 [PMID: 29276051]
  13. Int J Antimicrob Agents. 2009 Jan;33(1):33-9 [PMID: 18835761]
  14. J Med Microbiol. 2013 Nov;62(Pt 11):1747-1754 [PMID: 24000227]
  15. J Clin Microbiol. 2007 Dec;45(12):4054-7 [PMID: 17942662]
  16. Ann Dermatol. 2014 Apr;26(2):246-9 [PMID: 24882982]
  17. Antimicrob Agents Chemother. 2002 Jun;46(6):1946-52 [PMID: 12019113]
  18. Sci Rep. 2019 Nov 20;9(1):17127 [PMID: 31748527]
  19. Antimicrob Agents Chemother. 2013 Aug;57(8):3601-13 [PMID: 23689726]
  20. Clin Infect Dis. 2006 Mar 1;42(5):692-9 [PMID: 16447117]
  21. J Infect Dis. 1993 Feb;167(2):448-51 [PMID: 8421178]
  22. BMC Infect Dis. 2014 Feb 24;14:102 [PMID: 24564226]
  23. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416 [PMID: 15699079]
  24. Infect Immun. 2007 Dec;75(12):5597-608 [PMID: 17908807]
  25. Clin Infect Dis. 2013 Aug;57(3):349-58 [PMID: 23616495]
  26. J Antimicrob Chemother. 2006 Sep;58(3):689-92 [PMID: 16870647]
  27. Int J Infect Dis. 2015 Oct;39:25-33 [PMID: 26283551]
  28. PLoS One. 2014 Jun 09;9(6):e98091 [PMID: 24911658]
  29. J Antimicrob Chemother. 2001 Nov;48(5):723-6 [PMID: 11679563]
  30. Pathog Dis. 2014 Aug;71(3):292-301 [PMID: 24376225]
  31. Eur J Clin Microbiol Infect Dis. 2013 Oct;32(10):1291-4 [PMID: 23609511]
  32. Sci Rep. 2020 Oct 15;10(1):17518 [PMID: 33060737]

Word Cloud

Created with Highcharts 10.0.0PBRIFcombinationCRABgroupvitrovivofiveIMPMEMusedmodelantibioticsantibacterialBTGCSULpneumoniasynergisticeffectcombinedpolymyxinantimicrobialagentsalonecarbapenem-resistantmethoddetermineinhibitoryconcentrationtenstrainssixdrugsmouseeffectstreatmentbacterialloadinflammatoryfactorsIL-6TNF-αsignificantlysinglePURPOSE:studyactivitiesincludingimipenemmeropenemtigecyclinesulbactamrifampicinMETHODS:MicrobrothdilutionminimumMICcheckerboardfractionalindexFICIestablishedintranasalinstillationAb5075evaluateactivityRESULTS:resistancerate100%0%20%mainlyshowedadditivemaximalfollowedweakcompareduntreatedreducedlungtissueserumIL-1βdecreased<005valueslowertwoindividuallyCONCLUSION:exertedrobustisolatesbetteragentbestActivityCombinationsPolymyxinAntimicrobialsCarbapenem-ResistantAcinetobacterbaumanniiinfection

Similar Articles

Cited By (5)